It is reported that trabectedin could regulate the tumor micro-environment (TME) by decreasing the concentration of immune cells, such as monocytes and tumor-associated macrophages, and indirectly reducing the production of inflammatory mediators, such as interleukin-6, interleukin-8 and vascular endothelial growth factor, and affecting the expression of extracellular matrix-related genes [74]. The gene discussed is VEGFA; the disease is neoplasm.